|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.055 USD | 0.00% |
|
0.00% | -43.30% |
| 2023 | Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 2022 | Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022 | CI |
Remedent, Inc. reported earnings results for the six months ended September 30, 2015. For the period, the company reported net sales in Euro were EUR 1,327,022 as compared to EUR 1,318,154 for the six months ended September 30, 2014. Net income increased to $251,287 as compared to $142,835 for the six months ended September 30, 2014.
The increase of 75.92% is due to improved pricing and reduced costs.
| 1st Jan change | Capi. | |
|---|---|---|
| -43.30% | 1.06M | |
| -7.38% | 181B | |
| -0.46% | 108B | |
| -6.98% | 66.12B | |
| +2.65% | 50.65B | |
| +5.27% | 43.11B | |
| +6.18% | 40.74B | |
| +19.92% | 31.6B | |
| +15.82% | 25.56B | |
| -7.00% | 24.16B |
REMEDENT, INC. 
